文献速递鼻科

首次处方时长对过敏性鼻炎舌下免疫治疗依从性的影响

The effect of the standard length of the first prescription on the adherence to sublingual immunotherapy for patients with allergic rhinitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2020-03-29

该回顾性研究分析306例过敏性鼻炎患者的舌下免疫治疗数据,按首次处方时长分为不足3个月、3至6个月和超过6个月三组,发现首次处方超过6个月组依从率最高(86.05%),不足3个月组最低(41.18%),组间差异显著(p<0.05),建议在特定条件下将6个月作为首次处方标准时长。

要点

  • 首次处方超过6个月组依从率86.05%,显著高于3至6个月组69.57%和不足3个月组41.18%。
  • 三组首次处方平均长度分别为62.52±17.63、102.21±9.22和189.07±17.97天,组间差异显著(p<0.05)。
  • 不依从主要原因包括疗程长、取药不便、疗效不佳、副作用及其他原因。

核心结论

  • 在特定条件下,推荐将6个月作为首次处方标准时长,可显著提高过敏性鼻炎患者舌下免疫治疗的依从性。

研究设计与样本

  • 回顾性研究,纳入2017年1月至2018年6月期间开始舌下免疫治疗的306例过敏性鼻炎患者,按首次处方时长分为不足3个月组(102例)、3至6个月组(161例)和超过6个月组(43例)。

主要发现

  • 不足3个月组、3至6个月组和超过6个月组的依从患者分别为42例(41.18%)、112例(69.57%)和37例(86.05%)。
  • 三组不依从患者分别为60例(58.82%)、49例(30.43%)和6例(13.95%),依从与不依从比例组间差异显著(p<0.05)。
  • 三组首次处方平均长度分别为62.52±17.63天、102.21±9.22天和189.07±17.97天,组间差异显著(p<0.05)。

关键数值与推荐

  • 不依从原因包括舌下免疫治疗疗程长、取药不便、无效、副作用及其他原因。

临床怎么用

  • 对过敏性鼻炎患者启动舌下免疫治疗时,可考虑将首次处方时长设为6个月以提高治疗依从性。

局限性

  • 本研究为单中心回顾性研究,样本量有限,结论需在特定条件下谨慎推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor adherence to sublingual immunotherapy (SLIT) has become a major cause of unsatisfactory clinical efficacy for patients with allergic rhinitis (AR). This study was designed to identify the effect of different first prescription lengths on the adherence to SLIT. METHODS: The clinical data of 306 patients with AR who started SLIT between January 2017 and June 2018 were retrospectively reviewed. Patients were divided into 3 groups according to the length of their first prescription (group A: less than 3 months, group B: 3 to 6 months, group C: more than 6 months). The numbers of adherent or nonadherent patients in each group and the main reasons of nonadherence were analyzed. RESULTS: Groups A, B, and C included 102, 161, and 43 patients, respectively. The average lengths of the first prescription for group A, B, and C were 62.52 ± 17.63, 102.21 ± 9.22, and 189.07 ± 17.97 days. There were significance differences among the 3 groups (p < 0.05). There were 42 (41.18%), 112 (69.57%), and 37 (86.05%) adherent patients in group A, B, and C. There were 60 (58.82%), 49 (30.43%), and 6 (13.95%) nonadherent patients in group A, B, and C. There were significant differences in the proportions of adherent and nonadherent patients among the 3 groups (p < 0.05). The following reasons were cited for nonadherence to SLIT: the long course of SLIT; inconvenience of getting the prescription; ineffectiveness; side effects; and other reasons. CONCLUSION: Under certain conditions, 6 months is recommended as the standard length for the first prescription, which can significantly improve adherence to SLIT in patients with AR.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Jin M, Zhang L, Zhou G, et al. The effect of the standard length of the first prescription on the adherence to sublingual immunotherapy for patients with allergic rhinitis. Int Forum Allergy Rhinol. 2020. PMID: 32223075. doi:10.1002/alr.22553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。